Recent Updates
Recently added Catalysts

catheter lock

Phase 3

Central Line Associated Blood Stream Infections (CLABSI) | Small molecule | Infectious Disease |CorMedix Inc.|Last Updated: Jul 21, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment200
FDA Designations
No designations recorded
Clinical trial landscape

catheter lock · 1 trial · 1 indication

Phase 3 1
NCT06822426Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)Central Line Associated Blood Stream Infections (CLABSI)
RECRUITING200 Analytics
PHASE3RECRUITING
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
Central Line Associated Blood Stream Infections (CLABSI)
NCT06822426200
Unlock trial analytics
Study Endpoints
Primary Endpoints
Comparison between treatment groups of proportion of participants who experience a Central Line-Associated Bloodstream Infections (CLABSI) within 12 months of the start of the study
Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)

The proportion of participants who remain infection-free in the treatment groups will be compared, censoring participants who do not experience a CLABSI within 9 months, but fail to complete the 12 month follow-up period of the study.

Secondary Endpoints
Incidence of AEs, SAEs, treatment-emergent adverse events (TEAEs)
Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
Incidence of changes in laboratory evaluations, vital signs, or physical exam findings
Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
DefenCath®EXPERIMENTAL -
ControlACTIVE_COMPARATOR -
Interventions
NameTypeDescription
(taurolidine and heparin) catheter lock solutionDRUGfor central venous catheter installation use
HeparinDRUGHeparin
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites22

1. Participants who are resident within the US and Türkiye. 2. Participants who are male or female, aged ≥18 years at the time of consent. 3. Participants must sign and provide informed consent. 4. Participants who have a permanent tunneled CVC or permanent peripherally inserted central catheter (PI...

Countries:United StatesTurkey (Türkiye)
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJul 21, 2026NCT06822426lastUpdatePostDate: changed
MEDIUMMay 26, 2026NCT06822426primaryCompletionDate: changed
LOWMay 24, 2026NCT06822426studyFirstPostDate: changed